Halozyme Therapeutics Inc. has completed its previously announced acquisition of Elektrofi Inc., a biopharmaceutical company with a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon. Halozyme has acquired Elektrofi for an upfront payment of $750 million, subject to customary purchase price adjustments, and up to three $50 million milestone payments contingent on three separate product regulatory approvals, for a total consideration of up...